Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

Tamer A. Othmana Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA

Jianying Zhangb Department of Information Sciences, City of Hope Medical Center, Duarte, CA, USA

Matthew Meia Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA

Anthony S. Steina Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA

Stephen J. Formana Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA

Guido Marcuccia Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA

Vinod Pullarkata Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA

Ibrahim Aldossa Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USACorrespondence[email protected]

show all

"Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy." Leukemia & Lymphoma, 61(14), pp. 3532–3533

Disclosure statement

AS has served on Advisory boards for Stemline and Amgen, and on the Speaker Bureau for Stemline, Celgene and Amgen. GM is on Speaker’ bureau for Abbvie and Novartis, and serves on Advisory Board with Janssen Pharm. VP has served on the advisory boards for Abbvie and JAZZ Pharmaceuticals and is a member of Speakers bureau for JAZZ Pharmaceuticals, Amgen, Novartis and Abbvie. IA has served on the advisory board for Abbvie, Agios, and KiTE Pharma, consultant to Autolus Limited and served on the Speaker Bureau for JAZZ Pharmaceuticals. The remaining authors have no relevant conflict of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

Information for

Open access

Opportunities

Help and information

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature